Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 116 条

[21] One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study [J].

Genovese, Mark C. ;

Durez, Patrick ;

Richards, Hanno B. ;

Supronik, Jerzy ;

Dokoupilova, Eva ;

Aelion, Jacob A. ;

Lee, Sang-Heon ;

Codding, Christine E. ;

Kellner, Herbert ;

Ikawa, Takashi ;

Hugot, Sophie ;

Ligozio, Gregory ;

Mpofu, Shephard .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (03) :414-421

[22]

Gooderham M, 2015, Skin Therapy Lett, V20, P1

[23] Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study [J].

Gordon, Kenneth B. ;

Langley, Richard G. ;

Leonardi, Craig ;

Toth, Darryl ;

Menter, M. Alan ;

Kang, Sewon ;

Heffernan, Michael ;

Miller, Bruce ;

Hamlin, Regina ;

Lim, Liberata ;

Zhong, Jianhua ;

Hoffman, Rebecca ;

Okun, Martin M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :598-606

[24] Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial [J].

Gottlieb, AB ;

Evans, R ;

Li, S ;

Dooley, LT ;

Guzzo, CA ;

Baker, D ;

Bala, M ;

Marano, CW ;

Menter, A .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) :534-542

[25] A randomized trial of etanercept as monotherapy for psoriasis [J].

Gottlieb, AB ;

Matheson, RT ;

Lowe, N ;

Krueger, GG ;

Kang, S ;

Goffe, BS ;

Gaspari, AA ;

Ling, M ;

Weinstein, GD ;

Nayak, A ;

Gordon, KB ;

Zitnik, R .

ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1627-1632

[26]

Griffiths CE, 2014, 72 ANN M AM AC DERM

[27] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials [J].

Griffiths, Christopher E. M. ;

Reich, Kristian ;

Lebwohl, Mark ;

van de Kerkhof, Peter ;

Paul, Carle ;

Menter, Alan ;

Cameron, Gregory S. ;

Erickson, Janelle ;

Zhang, Lu ;

Secrest, Roberta J. ;

Ball, Susan ;

Braun, Daniel K. ;

Osuntokun, Olawale O. ;

Heffernan, Michael P. ;

Nickoloff, Brian J. ;

Papp, Kim .

LANCET, 2015, 386 (9993) :541-551

[28] Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis [J].

Griffiths, Christopher E. M. ;

Strober, Bruce E. ;

van de Kerkhof, Peter ;

Ho, Vincent ;

Fidelus-Gort, Roseanne ;

Yeilding, Newman ;

Guzzo, Cynthia ;

Xia, Yichuan ;

Zhou, Bei ;

Li, Shu ;

Dooley, Lisa T. ;

Goldstein, Neil H. ;

Menter, Alan .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (02) :118-128

[29] Certolizumab pegol for the treatment of psoriatic arthritis [J].

Hansen, Renata Baronaite ;

Kavanaugh, Arthur .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (03) :307-318

[30] Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J].

Harrington, LE ;

Hatton, RD ;

Mangan, PR ;

Turner, H ;

Murphy, TL ;

Murphy, KM ;

Weaver, CT .

NATURE IMMUNOLOGY, 2005, 6 (11) :1123-1132

← 1 2 3 4 5 6 7 8 9 10 →